These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 28535455)

  • 21. Virtual opioid agonist treatment: Alberta's virtual opioid dependency program and outcomes.
    Day N; Wass M; Smith K
    Addict Sci Clin Pract; 2022 Jul; 17(1):40. PubMed ID: 35902924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia.
    Jones NR; Shanahan M; Dobbins T; Degenhardt L; Montebello M; Gisev N; Larney S
    Drug Alcohol Rev; 2019 Sep; 38(6):690-698. PubMed ID: 31577058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of the 2014 military conflict in the east of Ukraine and the Autonomous Republic of the Crimea among patients receiving opioid agonist therapies.
    Meteliuk A; Sazonova Y; Goldmann E; Xu S; Liutyi V; Liakh T; Spirina T; Lekholetova M; Islam Z; Ompad DC
    J Subst Use Addict Treat; 2024 May; 160():209312. PubMed ID: 38336264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in Rates of Opioid Agonist Treatment and Opioid-Related Deaths for Youths in Ontario, Canada, 2013-2021.
    Rosic T; Kolla G; Leece P; Kitchen S; Gomes T
    JAMA Netw Open; 2023 Jul; 6(7):e2321947. PubMed ID: 37410463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study.
    Curtis M; Wilkinson AL; Dietze P; Stewart AC; Kinner SA; Winter RJ; Aitken C; Walker SJ; Cossar RD; Butler T; Stoové M
    Harm Reduct J; 2023 Mar; 20(1):42. PubMed ID: 36978089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short term health-related quality of life improvement during opioid agonist treatment.
    Nosyk B; Bray JW; Wittenberg E; Aden B; Eggman AA; Weiss RD; Potter J; Ang A; Hser YI; Ling W; Schackman BR
    Drug Alcohol Depend; 2015 Dec; 157():121-8. PubMed ID: 26511766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California.
    Krebs E; Enns B; Evans E; Urada D; Anglin MD; Rawson RA; Hser YI; Nosyk B
    Ann Intern Med; 2018 Jan; 168(1):10-19. PubMed ID: 29159398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of cocaine use in patients enrolled in opioid agonist therapy in Ontario, Canada.
    Franklyn AM; Eibl JK; Gauthier GJ; Pellegrini D; Lightfoot NE; Marsh DC
    Int J Drug Policy; 2017 Oct; 48():1-8. PubMed ID: 28666202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study.
    Gisev N; Bharat C; Larney S; Dobbins T; Weatherburn D; Hickman M; Farrell M; Degenhardt L
    Lancet Public Health; 2019 Jul; 4(7):e334-e342. PubMed ID: 31201133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opioid Agonist Therapy During Hospitalization Within the Veterans Health Administration: a Pragmatic Retrospective Cohort Analysis.
    Priest KC; Lovejoy TI; Englander H; Shull S; McCarty D
    J Gen Intern Med; 2020 Aug; 35(8):2365-2374. PubMed ID: 32291723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014.
    Guan Q; Khuu W; Spithoff S; Kiran T; Kahan M; Tadrous M; Martins D; Leece P; Gomes T
    Drug Alcohol Depend; 2017 Aug; 177():315-321. PubMed ID: 28733101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment Outcome Comparison Between Telepsychiatry and Face-to-face Buprenorphine Medication-assisted Treatment for Opioid Use Disorder: A 2-Year Retrospective Data Analysis.
    Zheng W; Nickasch M; Lander L; Wen S; Xiao M; Marshalek P; Dix E; Sullivan C
    J Addict Med; 2017; 11(2):138-144. PubMed ID: 28107210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing the impact of the slow-release oral morphine drug shortages in Ontario, Canada: A population-based time series analysis.
    Ledlie S; Tadrous M; McCormack D; Campbell T; Leece P; Kleinman RA; Kolla G; Besharah J; Smoke A; Sproule B; Gomes T
    Int J Drug Policy; 2023 Aug; 118():104119. PubMed ID: 37429161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using administrative data to predict cessation risk and identify novel predictors among new entrants to opioid agonist treatment.
    Bharat C; Degenhardt L; Dobbins T; Larney S; Farrell M; Barbieri S
    Drug Alcohol Depend; 2021 Nov; 228():109091. PubMed ID: 34592705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malmö Treatment Referral and Intervention Study (MATRIS)-36-month follow-up on retention and substance use among patients referred from needle exchange to opioid agonist treatment-The role of stimulant use at baseline.
    Troberg K; Bråbäck M; Isendahl P; Nilsson S; Dahlman D; Håkansson A
    J Subst Use Addict Treat; 2023 Aug; 151():209036. PubMed ID: 37054920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sleep reductions associated with illicit opioid use and clinic-hour changes during opioid agonist treatment for opioid dependence: Measurement by electronic diary and actigraphy.
    Bertz JW; Epstein DH; Reamer D; Kowalczyk WJ; Phillips KA; Kennedy AP; Jobes ML; Ward G; Plitnick BA; Figueiro MG; Rea MS; Preston KL
    J Subst Abuse Treat; 2019 Nov; 106():43-57. PubMed ID: 31540611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. State criminal justice policy context and opioid agonist treatment delivery among opioid treatment admissions, 2015.
    Mantha S; Mauro PM; Mauro CM; Martins SS
    Drug Alcohol Depend; 2020 Jan; 206():107654. PubMed ID: 31735533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interim opioid agonist treatment for opioid addiction: a systematic review.
    Samsó Jofra L; Puig T; Solà I; Trujols J
    Harm Reduct J; 2022 Jan; 19(1):7. PubMed ID: 35090475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of timely opioid agonist treatment initiation among veterans with and without HIV.
    Wyse JJ; Robbins JL; McGinnis KA; Edelman EJ; Gordon AJ; Manhapra A; Fiellin DA; Moore BA; Korthuis PT; Gaither JR; Gordon K; Skanderson M; Barry DT; Crystal S; Justice A; Kraemer KL
    Drug Alcohol Depend; 2019 May; 198():70-75. PubMed ID: 30878769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating the association between urine drug screening frequency and retention in opioid agonist treatment in Ontario, Canada: a retrospective cohort study.
    Morin KA; Dabous JR; Vojtesek F; Marsh D
    BMJ Open; 2022 Oct; 12(10):e060857. PubMed ID: 36223960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.